Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chronic administration of a HDAC inhibitor boosts microglial differentiation and treats neurological disease in a mouse model of intellectual disability.

ABSTRACT: Histone deacetylase inhibitors (HDACi) control chromatin states through histone acetylation and are of interest to treat neurological disorders. Defect in lysine-specific methyltransferase 2D (KMT2D) decreases the open chromatin mark H3K4me3 in brains of a mouse model of Kabuki Syndrome (KS), a rare intellectual disability disorder. We utilized single-cell RNA sequencing to explore the molecular landscape of microglia from the mouse hippocampus under different treatment conditions. untreated, PEG [dimethyl sulfoxide, 5% (DMSO) and polyethylene glycol, 45% (PEG)], HPBCD [DMSO (5%), PEG (45%), Hydroxypropyl-β-cyclodextrin, 0.2 gm/ml (HPBCD)], and TCF [DMSO (5%), PEG (45%), HPBCD (0.2 gm/ml), Vorinostat (5 mg/ml, Vo)]. Administration of a brain-permeant triple combination formulation (TCF) of 2-hydroxypropyl-b-cyclodextrin (HPBCD), polyethylene glycol-400 (PEG) and the FDA-approved histone deacetylase inhibitor (HDACi), vorinostat, weekly over 3 months, increased microglial levels (but failed to stimulate hippocampal neurogenesis). The differential gene expression analysis in combination with ingenuity pathway analysis predicted the specific effect of TCF on microglial histone 3, whose acetylation restored H3K4me3 independent of Kmt2D.This study examines the impact of the histone deacetylase inhibitor (Vo as a brain permeant formulation) on microglia in a Kabuki syndrome model.

ORGANISM(S): Mus musculus

PROVIDER: GSE290539 | GEO | 2026/02/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Hydroxypropyl-β-cyclodextrin spikes local inflammation that induces Th2 and Tfh responses to the coadministered antigen

Project description:Gene expression data from mouse organs after hydroxypropyl-β-cyclodextrin injection Cyclodextrins are commonly used as a safe excipient to enhance the solubility and bioavailability of hydrophobic pharmaceutical agents. In this study, we reprofiled hydroxypropyl-β-cyclodextrin (HP-β-CD) as a vaccine adjuvant, and found that it acts as a potent and unique adjuvant.

2015-02-15 | GSE63332 | GEO

Rapid genomic changes induced by PTH, SIK-inhibition, FGF23, and 1,25(OH)2D3 in the mouse kidney

Project description:In vivo ChIP-seq in mouse kidney: we examine the genomic recruitment of VDR, RXR, pCREB, CBP, CRTC2 (TORC2), SRC1, SRC3, BRD4, RNApolII, H3K9ac, H3K27ac, and H3K36me3 after intraperitoneal injection of 10 mg/kg body weight (bw) 1,25(OH)2D3 (in propylene glycol), 230 mg/kg bw PTH (1–84) (in phosphate buffered saline (PBS)), 50 mg/kg bw FGF23 (in PBS + 0.1% BSA), 30 mg/kg YKL-05-099 (PBS + 25mM HCl), 40 mg/kg SK-124 (15% HPBCD (hydroxypropyl β-cyclodextrin)), or vehicle (EtOH, PBS, or HPBCD). YKL-05-099 and SK-124 are salt-inducible kinase inhibitors that liberate CRTC2 from sequestration in the cytoplasm and allow CRTC2 translocation to the nucleus. Our findings show that these TFs and coactivators contribute to transcription of genes in the kidney involved in vitamin D metabolism, demonstrates SIK-inhibition as a key modulator of vitamin D metabolism, and provides molecular insight into the coordinated mechanistic actions of PTH, FGF23, and 1,25(OH)2D3 in the mouse kidney that regulate mineral homeostasis.

2022-09-30 | GSE206777 | GEO

Transciptome analysis of human aortic smooth muscle cells (HASMCs) with 2-hydroxypropyl-β-cyclodextrin (HPbCD) treatment

Project description:Transciptome analysis of human aortic smooth muscle cells (HASMCs) with 2-hydroxypropyl-β-cyclodextrin (HPbCD) treatment

| PRJNA565961 | ENA

Hydroxypropyl-Î²-cyclodextrin spikes local inflammation that induces Th2 and Tfh responses to the coadministered antigen

Project description:Gene expression data from mouse organs after hydroxypropyl-Î²-cyclodextrin injection Cyclodextrins are commonly used as a safe excipient to enhance the solubility and bioavailability of hydrophobic pharmaceutical agents. In this study, we reprofiled hydroxypropyl-Î²-cyclodextrin (HP-Î²-CD) as a vaccine adjuvant, and found that it acts as a potent and unique adjuvant. C57BL/6J mice (6 week old, male, n = 3) were injected i.d. or i.p. with a total volume of 200 micro liter of 30% HP-Î²-CD in PBS. The vehicle-control mice (n = 3) were injected with the same volume of PBS. After 6 h, the inguinal LNs, Liver, and Spleen were removed (within one hour for all samples) and global gene expression was obtained by Affymetrix GeneChip.

2015-02-15 | E-GEOD-63332 | biostudies-arrayexpress

Transcription profiling time series of human HeLa cells cultivated while sterol depleted from the medium

Project description:The aim of the experiment was to identify novel genes with relevance to cellular cholesterol metabolism. HeLa cells were cultivated while sterol was depleted from the medium by applying 2-Hydroxypropyl-cyclodextrin. RNA for expression profiling was isolated 3h, 4.5h and 6h after depletion.

2008-12-17 | E-TABM-599 | biostudies-arrayexpress

Programmatic Introduction of Parenchymal Cell Types in Blood Vessel Organoids

Project description:We developed a bottom-up engineering approach to building vascularized human tissue by combining genetic reprogramming with chemically directed organoid differentiation. As a proof of concept, we created neuro-vascular and myo-vascular organoids via transcription factor overexpression in vascular organoids. We characterized neuro-vascular organoids (iN-VOs) by single cell RNA-sequencing (scRNA-seq) to determine cell type composition and gene expression. Using droplet based scRNA-seq we analyzed over 26,000 cells across day 45 organoids grown under three conditions: 45 days of NEUROD1 overexpression (iN-VO, 45 Days Induction), 15 days of NEUROD1 overexpression (iN-VO, 15 Days Induction) and without overexpression (iN-VO, No Induction). We find that organoids contain a neural cell population only upon induction of NEUROD1 while maintaining the full set of endothelial and mesenchymal lineages present in uninduced vascular organoids.

2021-08-20 | GSE164268 | GEO

Quantitative proteomics and Real-Time PCR reveal downregulation of CXCR4 as a downstream effect of angiotensin-(1-7) treatment after experimental myocardial infarction

Project description:Angiotensin-(1-7) (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system. The cardioprotective role of Ang-(1-7) has been described due to its anti-inflammatory and anti-fibrotic activities. In this context, we investigated the impact of the oral formulation of Ang-(1-7) vehiculized in hydroxypropyl β-cyclodextrin (HPβCD) on cardiac proteome remodeling after experimental myocardial infarction. For this, Wistar male rats were submitted to short- (7 days) or long-term (60 days) oral treatment with HPβCD/Ang-(1-7) after induction of experimental myocardial infarction (MI)

2019-08-19 | PXD012896 | Pride

Global mRNA expression profiling of murine primary PDAC cells following JQ1 or SAHA monotherapy as well as JQ1-SAHA combination therapy

Project description:Global mRNA expression profiles of murine primary PDAC cells following JQ1 or SAHA monotherapy as well as JQ1-SAHA combination therapy were collected using Affymetix mouse whole genome array (Mouse Genome 430A 2.0 Array) . Primary PDAC cells isolated from Ptf1aCre/+;Kras+/LSL-G12D;p53lox/lox (Kras;p53) mice were treated either with JQ1 (100 nM) or SAHA (2000 nM) or vehicle 10% (2-Hydroxypropyl)-β-cyclodextrin (Sigma-Aldrich) or as combination therapy with the indicated dosage for monotherapy. Total RNA isolation was performed after 6 hours of treatment.

2015-09-20 | GSE64836 | GEO

Global mRNA expression profiling of murine primary PDAC cells following JQ1 or SAHA monotherapy as well as JQ1-SAHA combination therapy

2015-09-20 | E-GEOD-64836 | biostudies-arrayexpress

Transcriptome of 2-hydroxypropyl-beta-cyclodextrin treatment in Niemann-Pick disease type C1

Project description:Transcriptome of 2-hydroxypropyl-beta-cyclodextrin treatment in Niemann-Pick disease type C1

| PRJNA717336 | ENA